Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Damon Runyon scientists and industry partners gathered on Tuesday, March 24, for the 2026 Accelerating Cancer Cures Research Symposium, hosted by Amgen in Cambridge, Massachusetts.

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Most Profitable S&P 500 Stocks to Buy Now. On March 19, 2026, Wells Fargo raised ...

Amgen stock soared as much as 16% on Friday after it reported first-quarter earnings. The company talked up its experimental GLP-1 weight-loss drug, MariTide. The new weight loss drug could be ...

The White House’s direct-to-consumer (DTC) platform, TrumpRx, is steadily expanding its catalogue, with products from GSK and Amgen the latest to join the collection of drugs offered through the pr | ...

Why Amgen (AMGN) is on investors’ radar today Amgen (AMGN) is back in focus after recent share price moves, with the stock ...

Amgen (AMGN) closed at $361.13 in the latest trading session, marking a -1.4% move from the prior day. This change lagged the ...

Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IRS.

The Irish arm of bio-pharmaceutical giant Amgen has invested $407m (€353.3m) on capital expenditure on its Dun Laoghaire ...

The competition for treatments in the weight-loss market is heating up. Amgen is currently working on a promising anti-obesity medicine. There are plenty of other excellent reasons to buy the stock ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...